In line with that, a recent study exploring mechanisms to overcome drug resistance by applying a combination of Irinotecan and IAP small molecule antagonist BV6 revealed a chemosensitization by cIAP1/2 degradation and caspase-8/9 activation in mismatch repair (MMR)-proficient but not in MMR-deficient p53 mutated colorectal cancer cells and organoids [157]. This evidence concerns the gene TP53 and colorectal cancer.